Topics

Novartis Announces Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma

23:10 EDT 29 Sep 2019 | Drugs.com

Basel, September 30, 2019 – Novartis today announced that investigational, once-daily, inhaled QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) was superior to QMF149 (indacaterol acetate and...

Original Article: Novartis Announces Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma

NEXT ARTICLE

More From BioPortfolio on "Novartis Announces Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma"

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...